LP
Leap Therapeutics, Inc.
LPTX · NASDAQ
$0.77 -3.15% (-$0.03)
Market Cap $31.9M
P/E Ratio 9.62x
Div. Yield -
ROE 14.52%
Analiza
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Piotroski F-Score Moderate
4/9Valuation
75 /100
Cheap P/S 152.42x
P/B 0.21x
P/E 9.62x
Growth
100 /100
Growing Book val. growth 41.10%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak FCF margin 43,395.20%
Op. margin 31,465.10%
Gross margin 9,631.58%
Quality
33 /100
Poor Asset turnover 0.00x
ROA 9.40%
ROIC 25.07%
Debt
80 /100
Low Net debt/EBITDA 0.22x
Int. coverage -2,637.45x
Debt/Equity 0.00x
Stability
25 /100
Unstable EPS volatility 43.36%
Profitable years 1
Beta 0.09x
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o LPTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Douglas E. Onsi
Employees
52
Headquarters
Cambridge